|
|
Prosensa Raises 23 Million in New Equity Financing
- DAVID MOTT WILL JOIN PROSENSA’S SUPERVISORY BOARD (Persbericht)
25-1-2012 - Expansiefinanciering
Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing.
The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing Prosensa investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. David Mott, General Partner of NEA, will join Prosensa’s Supervisory Board.
|
|
Copyright (c) 2001- 2013 I.T. Media. Alle rechten voorbehouden.
|
|